Clinical Trials
12 trialsNCT01007032 2019-02-27
A Study of IMC-A12 in Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT00785538 2019-01-08
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Eli Lilly and Company
Phase 1 Completed
NCT01182883 2017-07-02
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01204476 2016-07-15
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00720174 2016-05-17
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01008566 2016-05-12
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01061749 2016-01-25
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00678769 2015-11-04
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00609141 2014-06-19
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
National Cancer Institute (NCI)
Phase 1 Completed
NCT00880282 2014-04-29
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
National Cancer Institute (NCI)
Phase 1 Completed
NCT00970580 2013-09-16
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Biogen
Phase 1 Completed
NCT00785941 2011-10-13
A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
Eli Lilly and Company
Phase 1 Completed